Coltac is committed to discovering the next generation of molecular glues by harnessing the power of our bacteria-based, synthetic positive selection screening system.
Implementing advanced structural expertise embedded in rationale high-throughput screening (“HTS”)
We use split antibiotic resistance protein fragments fused to Ub and targets, co-expressed in bacteria with a synthetic ubiquitylation apparatus, to identify molecular glues that enhance target ubiquitylation
Accelerated hit-to-lead optimization by iterating cycles of lead optimization leveraging bacterial growth as a positive signal screening platform
Coltac’s discovery processes seamlessly integrate advanced in-silico screening, powered by deep structural expertise, with a patented bacterial-based HTS platform that generates positive signals for superior signal-to-noise outcomes.
Together, these technologies form BOND+, an elegant, efficient, and highly selective discovery platform.
Coltac’s discovery processes seamlessly integrate advanced in-silico screening, powered by deep structural expertise, with a patented bacterial-based HTS platform that generates positive signals for superior signal-to-noise outcomes.
Together, these technologies form BOND+, an elegant, efficient, and highly selective discovery platform.
Coltac is already working with unique ligases on high-value targets. Our rapid transition from virtual screening to high-throughput bacterial validation accelerates the development of next-generation drugs for oncology and other therapeutic areas.
We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.
We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.
We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.
Our team of visionary scientists and innovators drives Coltac’s mission to advance molecular glue discovery and create transformative therapies.